NCT02598661 2026-01-05Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Geron CorporationPhase 2/3 Active not recruiting289 enrolled 35 charts 1 FDA